Your browser doesn't support javascript.
loading
Reliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies.
Hidetsugu Fujigaki; Masao Takemura; Michiko Osawa; Aki Sakurai; Kentaro Nakamoto; Koichi Seto; Takashi Fujita; Tadayoshi Hata; Hidehiko Akiyama; Yohei Doi; Kuniaki Saito.
Affiliation
  • Hidetsugu Fujigaki; Fujita Health University Graduate School of Health Sciences
  • Masao Takemura; Fujita Health University Graduate School of Health Sciences
  • Michiko Osawa; Fujita Health University Hospital
  • Aki Sakurai; Fujita Health University School of Medicine
  • Kentaro Nakamoto; Fujita Health University Graduate School of Health Sciences
  • Koichi Seto; Fujita Health University
  • Takashi Fujita; Fujita Health University Hospital
  • Tadayoshi Hata; Fujita Health University Hospital
  • Hidehiko Akiyama; Fujita Health University Graduate School of Health Sciences
  • Yohei Doi; Fujita Health University School of Medicine
  • Kuniaki Saito; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences
Preprint in English | medRxiv | ID: ppmedrxiv-20140475
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
BackgroundSeveral immunochromatographic serological test kits have been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, but their relative performance and potential clinical utility is unclear. MethodsThree commercially available serological test kits were evaluated using 99 serum samples collected from 29 patients diagnosed with coronavirus disease 2019 (COVID-19). ResultsThe IgM antibody-positive rates of the three serological test kits for samples taken at the early stage of the disease (0-6 days after onset) were 19.0%, 23.8%, and 19.0%, respectively. The IgM antibody-positive rates over the entire period were 21.2%, 60.6%, and 15.2%, respectively. The IgG antibody-positive rates for samples taken after 13 days of onset were 100.0%, 97.6%, and 97.6%, respectively. ConclusionThere were large differences among the results of the three test kits. Only few cases showed positive results for IgM in the early stage of disease and the IgM antibody-positive rates over the entire period were low, suggesting that the kits used in this study were unsuitable for diagnosis of COVID-19. The IgG antibody was positive in almost all samples after 13 days of onset, suggesting that it may be useful for determining infections in the recent past.
License
cc_by_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Prognostic study Language: English Year: 2020 Document type: Preprint
...